Psilocybin
Raison et al., JAMA, 2023
- Design
- Phase 2, randomized, double-blind trial at 11 US sites comparing one psilocybin dose with a niacin placebo, both with psychological support.
- Who took part
- 104 adults aged 21 to 65 with major depression of moderate or greater severity.
- Findings
- Psilocybin reduced depression scores more than the niacin placebo over six weeks.
- Limitations
- Single dose with six weeks of follow-up. People taking psychiatric medicines had to taper off first.
